1. Comparison of Two Quantitative PCR–Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts
- Author
-
Ting-Yu Huang, Tang-Her Jaing, Ying-Jung Huang, Jiunn-Ming Sheen, Chia-Hui Chang, Ting-Chi Yeh, Lee-Yung Shih, Shyh-Shin Chiou, Shih-Hsiang Chen, Po-Nan Wang, Kang-Hsi Wu, Te-Kau Chang, Ming-Chung Kuo, Hsi-Che Liu, Tung-Liang Lin, Shih-Chung Wang, Chih-Cheng Hsiao, Shu-Fen Hu, and Chao-Ping Yang
- Subjects
Neoplasm, Residual ,Oncogene Proteins, Fusion ,Concordance ,Fusion Proteins, bcr-abl ,Immunoglobulins ,Gene Rearrangement, T-Lymphocyte ,Real-Time Polymerase Chain Reaction ,Sensitivity and Specificity ,Pathology and Forensic Medicine ,Recurrence ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,hemic and lymphatic diseases ,medicine ,Humans ,Receptor ,Gene ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,business.industry ,T-cell receptor ,Reproducibility of Results ,Molecular biology ,Minimal residual disease ,medicine.anatomical_structure ,Real-time polymerase chain reaction ,Core Binding Factor Alpha 2 Subunit ,embryonic structures ,biology.protein ,Molecular Medicine ,Bone marrow ,Antibody ,business ,Follow-Up Studies - Abstract
Two quantitative PCR (qPCR)–based methods, for clonal immunoglobulin or T-cell receptor gene (Ig/TCR) rearrangements and for fusion transcripts, are widely used for the measurement of minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL). MRD of bone marrow samples from 165 patients carrying the three major fusion transcripts, including 74 BCR-ABL1, 54 ETV6-RUNX1, and 37 TCF3-PBX1, was analyzed by using the two qPCR-based methods. The correlation coefficient of both methods was good for TCF3-PBX1 (R2 = 0.8088) and BCR-ABL1 (R2 = 0.8094) ALL and moderate for ETV6-RUNX1 (R2 = 0.5972). The concordance was perfect for TCF3-PBX1 ALL (97.2%), substantially concordant for ETV6-RUNX1 ALL (87.1%), and only moderate for BCR-ABL1 ALL (70.6%). The discordant MRD, positive for only one method with a difference greater than one log, was found in 4 of 93 samples (4.3%) with ETV6-RUNX1, 31 of 245 samples (12.7%) with BCR-ABL1, and none of TCF3-PBX1 ALL. None of the eight non-transplanted patients with BCR-ABL1-MRD (+)/Ig/TCR-MRD (–) with a median follow-up time of 73.5 months had hematologic relapses. Our study showed an excellent MRD concordance between the two qPCR-based methods in TCF3-PBX1 ALL, whereas qPCR for Ig/TCR is more reliable in BCR-ABL1 ALL.
- Published
- 2021
- Full Text
- View/download PDF